

Exhibit No.	Description
10.15†	Assignment, Transfer and Assumption Agreement between ViroPharma Incorporated and Eli Lilly and Company dated October 18, 2004.(15) (Exhibit 2.1)
10.16†	Amendment No. 1 to the Assignment, Transfer and Assumption Agreement between ViroPharma Incorporated and Eli Lilly and Company dated November 8, 2004.(15) (Exhibit 2.2)
10.17†	License Agreement between ViroPharma Incorporated and Schering Corporation dated November 3, 2004. (16)
	(Exhibit 2.1)
10.18††	ViroPharma Severance Plan. (19) (Exhibit 10.37)
10.19††	ViroPharma Cash Bonus Plan. (28) (Exhibit 10.22)
10.20††	ViroPharma Board Compensation Policy. (27) (Exhibit 10.1)
10.21††	Amended and Restated 1995 ViroPharma Stock Option and Restricted Share Plan. (18)
10.22††	2005 ViroPharma Stock Option and Restricted Share Plan. (24)
10.23††	Form Of Non-Qualified Stock Option Agreement For Member Of The Board Of Director. (20) (Exhibit 10.2)
10.24††	Form Of Non-Qualified Stock Option Agreement. (20) (Exhibit 10.3)
10.25††	Form of Incentive Stock Option Agreement. (20) (Exhibit 10.4)
10.26†	Master Agreement by and between OSG Norwich Pharmaceuticals, Inc. and ViroPharma Incorporated effective as of December 1, 2005. (21) (Exhibit 10.41)
10.27†	Project Agreement No. 1 by and between OSG Norwich Pharmaceuticals, Inc. and ViroPharma Incorporated. (21) (Exhibit 10.42)
10.28†	Bulk Supply Agreement between ViroPharma and Alpharma Inc. dated April 13, 2006. (22) (Exhibit 10.1)
10.29†	Project Agreement No. 2 by and between OSG Norwich Pharmaceuticals, Inc. and ViroPharma Incorporated dated May 15, 2006. (22) (Exhibit 10.2)
10.30††	Separation Agreement between the Company and Joshua Tarnoff dated as of September 15, 2006. (23) (Exhibit 10.1)
10.31	Real Estate Purchase Agreement between LV Associates, L.P. and the Company dated December 22, 2006. (28) (Exhibit 10.33)
10.32	Confirmation of Convertible Bond Hedge Transaction, dated as of March 20, 2007, by and between ViroPharma Incorporated and Credit Suisse International and Credit Suisse, New York Branch, as agent for Credit Suisse International. (26) (Exhibit 10.1)
10.33	Confirmation of Convertible Bond Hedge Transaction, dated as of March 20, 2007, by and between ViroPharma Incorporated and Wells Fargo Bank, National Association. (26) (Exhibit 10.2)
10.34	Confirmation of Issuer Warrant Transaction dated as of March 20, 2007, by and between ViroPharma Incorporated and Credit Suisse International and Credit Suisse, New York Branch, as agent for Credit Suisse International. (26) (Exhibit 10.3)
10.35	Confirmation of Issuer Warrant Transaction, dated as of March 20, 2007, by and between ViroPharma Incorporated and Wells Fargo Bank, National Association.(26) (Exhibit 10.4)
10.36	Amendment to Confirmation of Issuer Warrant Transaction dated as of March 22, 2007, by and between ViroPharma Incorporated and Credit Suisse International and Credit Suisse, New York Branch, as agent for Credit Suisse International. (26) (Exhibit 10.4)
10.37	Amendment to Confirmation of Issuer Warrant Transaction, dated as of March 22, 2007, by and between ViroPharma Incorporated and Wells Fargo Bank, National Association. (26) (Exhibit 10.5)
10.38†*	Amended and Restated Bulk Supply Agreement between ViroPharma and Alpharma Inc. dated October 26, 2007.
14	Code of Conduct and Ethics. (14)(Exhibit 14)
21*	List of Subsidiaries.